Tag:
RDEA594
Latest Headlines
Latest Headlines
Ardea's Phase II gout drug shows promise
San Diego-based Ardea Biosciences has unveiled promising Phase II results from a trial of its oral gout drug RDEA594. When combined with the standard treatment allopurinol, 89 percent of patients
Ardea shares spike on promising PhIIb gout drug data
Shares of Ardea Biosciences ( RDEA ) surged 23 percent in after-market trading yesterday evening after the developer posted positive data for its dose-ranging, mid-stage trial of its experimental gout
